India As A Global Biosimilar’s Hub: Economic Impact, Make-In-India Potential, And Emerging Challenges

The treatment of chronic and sometimes fatal illnesses has been completely transformed by biologics, especially in the areas of cancer, autoimmune diseases, and metabolic disorders. However, in underdeveloped nations like India, its exorbitant cost severely restricts accessibility. Biosimilars, which are biological products that closely resemble authorized reference biologics, provide an affordable substitute without sacrificing quality, safety, or efficacy. India is becoming a global centre for biosimilars thanks to its extensive pharmaceutical manufacturing base and knowledge of generics. This paper examines the financial effects of biosimilars on India's healthcare system, assesses how the "Make in India" campaign has strengthened domestic production, and identifies important market, scientific, and regulatory issues. Increased patient access, significant cost reductions, and better healthcare sustainability are all facilitated by biosimilars. However, issues such low physician acceptance, regulatory heterogeneity, and immunogenicity continue to exist. To reach India's full potential as a worldwide leader in biosimilars, strategic investments in research, regulatory harmonization, and awareness campaigns are necessary.